Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?
By the Top Tier Newswire AI Desk · November 16, 2026 at 11:39 AM ET · reviewed against 22 wire stories
SUMMIT THERAPEUTICS (SMMT) is down -14.98% in the latest session. Our newswire has captured 22 stories on SMMT across 13 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Summit Therapeutics (SMMT) shares fell 14.98% to $12.03, driven by the FDA’s decision to decline approval for its lung cancer drug, ivonescimab. The regulator issued a Complete Response Letter, indicating the therapy needs to demonstrate it can help patients live longer.
What Happened
The FDA issued a Complete Response Letter for the Biologics License Application covering ivonescimab. The agency stated that the drug showed a progression-free survival benefit but lacked statistically significant improvement in overall survival. This regulatory setback prompted immediate reactions from analysts. Barclays lowered its price target on the stock to $18 from $20 while maintaining an Equal Weight rating. Evercore ISI Group also adjusted its stance, lowering its price target to $33 while maintaining an Outperform rating. The move marks a significant hurdle for the next-generation cancer therapy, which is backed by AstraZeneca.
What The Data Shows
The stock opened at $11.56, representing an 18.3% gap down from the prior close of $14.15. Trading volume reached 10.7 million shares, which is 1.9 times the three-month daily average. The session high was $13.28 at 9:35 AM ET, while the low was $11.45 at 7:00 AM ET. The company has a market capitalization of $11.3 billion and is currently unprofitable, with trailing twelve-month earnings per share of negative $1.07. Revenue for the same period was negative 100.0%. The stock is trading near its 52-week low, with a range of $12.07 to $29.23. Over the last eight sessions, the stock had already declined 12.5% from $16.17 to $14.15. On November 16, 2026, the stock printed three fresh 52-week highs and ten fresh 52-week lows.
What To Watch
Investors will monitor how the company responds to the FDA’s feedback and whether it plans to resubmit the application. The broader biotech sector is also watching for potential sentiment shifts following recent regulatory decisions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · Nov 16 session (5-min) · -16.25% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 22 stories · 31/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoStocktwits NewsBEARISH 34Analyst
SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
Barclays lowered its price target on Summit Therapeutics to $18 from $20 while maintaining an 'Equal Weight' rating, according to The Fly.
4d agoGuruFocusBEARISH 42Analyst
SMMT Maintained by Evercore ISI Group -- Price Target Lowered to $33
Summit Therapeutics Inc (SMMT) Analyst Rating Update On October 3, 2023, Summit Therapeutics Inc (SMMT) received an updated rating action from Evercore ISI G
4d agoQuartzBEARISH 22General
FDA declined to approve Summit Therapeutics' lung cancer drug
4d agoBarron'sBEARISH 34General
Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
4d agoMarketWatchBEARISH 22General
The FDA declined to approve one of biotech’s most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
4d agoThe FlyNEUTRAL 48General
San Mateo Midstream announces offering of $750M senior notes
4d agoStockTitanNEUTRAL 52General
San Mateo Midstream Announces Offering of $750 Million of Senior Notes Due 2031
4d agoTipRanksBEARISH 34Product/PR
Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab
Summit Therapeutics ( ($SMMT) ) has provided an announcement. On November 15, 2026, Summit Therapeutics announced that the FDA issued a CRL for its BLA covering ivo...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →